University of Leicester
dyad165 (1).pdf (1.07 MB)

Cohort Profile: Post-hospitalisation COVID-19 study (PHOSP-COVID)

Download (1.07 MB)
journal contribution
posted on 2024-03-11, 11:29 authored by Omer Elneima, Hamish J. C. McAuley, Olivia C Leavy, James D. Chalmers, Ling-Pei Ho, Michael MarksMichael Marks, Krisnah Poinasamy, Betty Raman, Aarti Shikotra, Amisha Singapuri, Marco Sereno, Victoria C. Harris, Linzy Houchen-Wolloff, Ruth M. Saunders, Neil J Greening, Matthew Richardson, Jennifer K. Quint, Andrew Briggs, Annemarie B Docherty, Steven Kerr, Ewen M Harrison, Nazir I Lone, Mathew Thorpe, Liam G. Heaney, Keir E. Lewis, Raminder Aul, Paul Beirne, Charlotte E Bolton, Jeremy S. Brown, Gourab Choudhury, Nawar Diar Bakerly, Nicholas Easom, Carlos Echevarria, Jonathan Fuld, Nick Hart, John R. Hurst, Mark G. Jones, Dhruv Parekh, Paul Pfeffer, Najib M Rahman, Sarah L Rowland-Jones, AA Roger Thompson, Caroline J. Jolley, Ajay M Shah, Dan G. Wootton, Trudie Chalder, Melanie J Davies, Anthony De Soyza, John R. Geddes, William Greenhalf, Simon HellerSimon Heller, Luke S Howard, Joseph JacobJoseph Jacob, R Gisli Jenkins, Janet M Lord, William D-C Man, Gerry P. McCann, Stefanie Neubauer, Peter JM Openshaw, Joanna C. Porter, Matthew J. Rowland, Janet T Scott, Malcolm G Semple, Sally J. Singh, David C. Thomas, Mark Toshner, Nikki Smith, Aziz Sheikh, Christopher E Brightling, Louise V. Wain, Rachael A. Evans, PHOSP-COVID collaborative group

Key Features

The Post-Hospitalisation COVID-19 (PHOSP-COVID) study is a national UK multicentre cohort study of patients who were hospitalized for COVID-19 and subsequently discharged.

PHOSP-COVID was established to investigate the medium- and long-term sequelae of severe COVID-19 requiring hospitalization, understand the underlying mechanisms of these sequelae, evaluate the medium- and long-term effects of COVID-19 treatments and to serve as a platform to enable future studies, including clinical trials.

Data collected covered a wide range of physical measures, biological samples and patient-reported outcome measures (PROMs).

Participants could join the cohort either in Tier 1 only with remote data collection using hospital records, a PROMs app and postal saliva sample for DNA; or in Tier 2 in which they were invited to attend two specific research visits for further data collection and biological research sampling. These research visits occurred at 5 (range 2–7) months and 12 (range 10–14) months post-discharge. Participants could also participate in specific nested studies (Tier 3) at selected sites.

All participants were asked to consent to further follow-up for 25 years via linkage to their electronic healthcare records and to be re-contacted for further research.

In total, 7935 participants were recruited from 83 UK sites: 5238 to Tier 1 and 2697 to Tier 2, between August 2020 and March 2022.

Cohort data are held in a Trusted Research Environment and samples stored in a central biobank. Data and samples can be accessed upon request and subject to approvals from


Author affiliation

Department of Respiratory Sciences, University of Leicester


  • VoR (Version of Record)

Published in

International Journal of Epidemiology






Oxford University Press (OUP)



Copyright date


Available date




Usage metrics

    University of Leicester Publications


    No categories selected



    Ref. manager